Bioinformatics analyses combined microarray identify the deregulated microRNAs in oral cancer

Cui,Jing; Li,Dalu; Zhang,Wenmei; Shen,Liang; Xu,Xin

doi:10.3892/ol.2014.2070

Bioinformatics analyses combined microarray identify the deregulated microRNAs in oral cancer

Authors:
- Jing Cui
- Dalu Li
- Wenmei Zhang
- Liang Shen
- Xin Xu
View Affiliations

Affiliations: Department of Oral and Maxillofacial Surgery, Jinan Stomatologic Hospital, Jinan, Shandong 250010, P.R. China, Department of Oral Surgery, Jinan Stomatological Hospital, Jinan, Shandong 250010, P.R. China, Department of Obstetrics and Gynecology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong 250010, P.R. China, School of Stomatology, Shandong University, Jinan, Shandong 250010, P.R. China
Published online on: April 15, 2014 https://doi.org/10.3892/ol.2014.2070
Pages: 218-222

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MicroRNAs (miRNAs) are important in the regulation of cell growth, differentiation, apoptosis and carcinogenesis. The overexpression of oncogenic miRNAs or the underexpression of tumor suppressor miRNAs exhibits a critical function in the tumorigenesis of oral cancer. The aim of the present study was to identify differentially expressed miRNAs (DE‑miRNAs), which may differentiate oral cancer from normal tissues, as well as the molecular signatures that differ in tumor histology. The miRNA expression profiles of GSE28100 [the Gene Expression Omnibus (GEO) accession number] were downloaded from the GEO database and an independent sample t‑test was used to identify statistical differences between the DE‑miRNAs of the oral cancer patients and the healthy control subjects. The target genes of DE‑miRNA were retrieved from the miRecords database. Furthermore, a protein‑protein interaction network was constructed using the Search Tools for the Retrieval of Interacting Genes database and Cytoscape software. A total of 15 DE‑miRNAs were identified and among them, hsa‑miR‑15a drew specific attention. Gene Ontology analysis revealed that the target genes of fibroblast growth factor (FGF)2 are involved in the progression of oral cancer. Furthermore, functional analysis indicated that the FGF‑receptor signaling pathway was significantly upregulated in oral cancer. hsa‑miR‑15a is important in the regulation of oral cancer and thus, may present a potential biomarker for the prediction of oral cancer progression.

View Figures

View References

1	Zygogianni AG, Kyrgias G, Karakitsos P, et al: Oral squamous cell cancer: early detection and the role of alcohol and smoking. Head Neck Oncol. 3:22011.
2	Zini A, Czerninski R and Sgan-Cohen HD: Oral cancer over four decades: epidemiology, trends, histology, and survival by anatomical sites. J Oral Pathol Med. 39:299–305. 2010.
3	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013.
4	Mirnezami AH, Pickard K, Zhang L, Primrose JN and Packham G: MicroRNAs: key players in carcinogenesis and novel therapeutic targets. Eur J Surg Oncol. 35:339–347. 2009.
5	Ruan K, Fang X and Ouyang G: MicroRNAs: novel regulators in the hallmarks of human cancer. Cancer Lett. 285:116–126. 2009.
6	Cicatiello L, Mutarelli M, Grober OM, et al: Estrogen receptor alpha controls a gene network in luminal-like breast cancer cells comprising multiple transcription factors and microRNAs. Am J Pathol. 176:2113–2130. 2010.
7	Siow M, Karen Ng L, Vincent Chong V, et al: Dysregulation of miR-31 and miR-375 expression is associated with clinical outcomes in oral carcinoma. Oral Dis. Apr 17–2013.(Epub ahead of print). DOI: 10.1111/odi.12118
8	Jung HM, Phillips BL, Patel RS, et al: Keratinization-associated miR-7 and miR-21 regulate tumor suppressor reversion-inducing cysteine-rich protein with kazal motifs (RECK) in oral cancer. J Biol Chem. 287:29261–29272. 2012.
9	Franceschini A, Szklarczyk D, Frankild S, et al: STRING v9.1: protein-protein interaction networks, with increased coverage and integration. Nucleic Acids Res. 41:D808–D815. 2013.
10	Cimmino A, Calin GA, Fabbri M, et al: miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA. 102:13944–13949. 2005.
11	Calin GA, Cimmino A, Fabbri M, et al: MiR-15a and miR-16-1 cluster functions in human leukemia. Proc Natl Acad Sci USA. 105:5166–5171. 2008.
12	Urbich C, Kuehbacher A and Dimmeler S: Role of microRNAs in vascular diseases, inflammation, and angiogenesis. Cardiovasc Res. 79:581–588. 2008.
13	Bonci D, Coppola V, Musumeci M, et al: The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med. 14:1271–1277. 2008.
14	Bandi N, Zbinden S, Gugger M, et al: miR-15a and miR-16 are implicated in cell cycle regulation in a Rb-dependent manner and are frequently deleted or down-regulated in non-small cell lung cancer. Cancer Res. 69:5553–5559. 2009.
15	Xin C, Buhe B, Hongting L, et al: MicroRNA-15a promotes neuroblastoma migration by targeting reversion-inducing cysteine-rich protein with Kazal motifs (RECK) and regulating matrix metalloproteinase-9 expression. FEBS J. 280:855–866. 2013.
16	Ricieri Brito JA, Gomes CC, Santos Pimenta FJ, et al: Reduced expression of mir15a in the blood of patients with oral squamous cell carcinoma is associated with tumor staging. Exp Ther Med. 1:217–221. 2010.
17	Okada-Ban M, Thiery JP and Jouanneau J: Fibroblast growth factor-2. Int J Biochem Cell Biol. 32:263–267. 2000.
18	Dow JK and deVere White RW: Fibroblast growth factor 2: its structure and property, paracrine function, tumor angiogenesis, and prostate-related mitogenic and oncogenic functions. Urology. 55:800–806. 2000.
19	Chalkiadaki G, Nikitovic D, Berdiaki A, et al: Fibroblast growth factor-2 modulates melanoma adhesion and migration through a syndecan-4-dependent mechanism. Int J Biochem Cell Biol. 41:1323–1331. 2009.
20	Giri D, Ropiquet F and Ittmann M: Alterations in expression of basic fibroblast growth factor (FGF) 2 and its receptor FGFR-1 in human prostate cancer. Clin Cancer Res. 5:1063–1071. 1999.
21	Cross MJ and Claesson-Welsh L: FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition. Trends Pharmacol Sci. 22:201–207. 2001.
22	Lau MT, So WK and Leung PC: Fibroblast growth factor 2 induces E-cadherin down-regulation via PI3K/Akt/mTOR and MAPK/ERK signaling in ovarian cancer cells. PLoS One. 8:e590832013.
23	Kelleher FC, O’Sullivan H, Smyth E, McDermott R and Viterbo A: Fibroblast growth factor receptors, developmental corruption and malignant disease. Carcinogenesis. 34:2198–2205. 2013.
24	Liang G, Chen G, Wei X, Zhao Y and Li X: Small molecule inhibition of fibroblast growth factor receptors in cancer. Cytokine Growth Factor Rev. 24:467–475. 2013.
25	Weiss J, Sos ML, Seidel D, et al: Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med. 2:62ra932010.
26	Dutt A, Salvesen HB, Chen TH, et al: Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proc Natl Acad Sci USA. 105:8713–8717. 2008.
27	Kunii K, Davis L, Gorenstein J, et al: FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival. Cancer Res. 68:2340–2348. 2008.